Article
Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction.
Cardiovascular diabetology - 9 Feb 2016
Bakhashab Sherin, Ahmed Fahad W, Schulten Hans-Juergen, Bashir Ayat, Karim Sajjad, Al-Malki Abdulrahman L, Gari Mamdooh A, Abuzenadah Adel M, Chaudhary Adeel G, Alqahtani Mohammed H, Lary Sahira, Ahmed Farid, Weaver Jolanta U
Abstract excerpt
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes mellitus (DM). To identify the most effective treatment for CVD, it is paramount to understand the mechanism behind cardioprotective therapies. Although metformin has been shown to reduce CVD in Type-2 DM clinical trials, the underlying mechanism remains unexplored. CD34(+) cell-based therapies offer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.